For the past two decades, attention to sepsis has intensified because of growing recognition that it is one of the most common and lethal conditions we face, whether as a patient, provider, hospital, or public health agency. Until now, we have had an incomplete accounting of the global epidemiology of sepsis, with several reports from high-income countries and relatively few from countries of low and middle income (LMICs). In The Lancet, Kristina Rudd and colleagues 1 present an analysis of data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017, which is the most comprehensive assessment of the worldwide sepsis burden to date. Their results reinforce what many researchers already suspected: sepsis has had an extraordinary impact throughout the world and the toll is greatest in LMICs.
GBD is a consortium of more than 3600 researchers studying the world's most important health problems.
GBD 2017 contains more than 1 billion datapoints for 282 underlying causes of death in 195 countries. 2 However, because sepsis has conventionally been considered an intermediate rather than an underlying cause of death, it has not been properly accounted. 3, 4 Rudd and colleagues deployed a sequential multistep modelling strategy that leveraged GBD resources to produce the first global estimates of sepsis epidemiology. They used vital records to model (from multiple causes of death) the fraction of deaths for each underlying cause that were sepsis-related, then multiplied these sepsis fractions by countries' death counts for each underlying cause of death to ascertain sepsis deaths in each country. To estimate sepsis incidence, they modelled sepsis casefatality rates from hospital discharge records for each of the underlying causes and used these case-fatality rates as divisors to calculate sepsis incidence from death counts. For 2017, Rudd and colleagues reported that the global A global accounting of sepsis of the disease (favouring CABG for severe lesions) and patient preference (usually favouring PCI). All investigators, whether surgeons or interventionalists, should be encouraged to come together to form multidisciplinary research teams and to combine their intellectual and material resources to design and execute proper trials that address the unmet needs of patients. We must take advantage of this scientific momentum and strive to reach clear conclusions that could potentially generate a breakthrough in care for patients with left main coronary disease. burden of sepsis was twice that of previous estimates, with an estimated 49 million cases and 11 million deaths. Moreover, the annual number of sepsis cases over the past two decades fell worldwide by more than 50%. Yet sepsis still contributed to almost 20% of all deaths every year in the world, more than 20 deaths every minute. As expected from findings of previous studies, 5,6 the burden of sepsis was associated with income and development in each country, with approximately 85% of all sepsis-related deaths in LMICs. Despite differences in types of patient and health-care resources, the longitudinal changes are remarkably similar across disparate regions and countries, with the exception of southern sub-Saharan Africa. The implications of Rudd and colleagues' findings must be viewed in context with the constraints of the analysis, because modelling assumptions and imputation steps can introduce bias. The model inputs to estimate the burden of sepsis for 195 countries came from the vital records of four countries (Brazil, Mexico, Taiwan, and the USA), and data for hospital case-fatalities were obtained from ten countries (Austria, Brazil, Canada, Chile, Georgia, Italy, Mexico, New Zealand, Philippines, and the USA), resulting in extrapolation from countries of high and middle incomes to low-income countries. Because some continents (notably Africa) are not represented as original sepsis data sources, longitudinal trends might be unreliable. Hypothetically, improvements in Brazil as a primary data source country could create the appearance of benefits for sub-Saharan Africa, irrespective of actual local changes. Moreover, compared with studies not affected by the vagaries of administrative coding, 7 Rudd and colleagues' departure from the exemplar implicit and explicit coding strategies could have contributed to the higher rates of sepsis. The effect of including non-infectious conditions (eg, pulmonary embolism) and excluding infectious conditions (eg, non-miliary tuberculosis) in the implicit definition, and broad inclusion of maternal and paediatric infection codes (eg, disorders of amniotic fluid and membranes or neonatal bradycardia) within the explicit sepsis definition might unpredictably affect case-finding in each country. 8, 9 Furthermore, understanding the total burden of sepsis requires several aspects not yet included, such as healthcare use before and after sepsis, particularly to capture post-sepsis complications such as musculoskeletal and neurocognitive deficits, loss of productivity from inability to return to work, and years of life lost. This latest study from GBD 2017 is the first comprehensive global report on the epidemiology of sepsis. It takes the first steps to recording the burden of sepsis throughout the world, including new considerations such as the frequency of sepsis complicating injuries and non-communicable diseases. In view of the complexity in producing global estimates, it is important that countries purported to have a high burden of sepsis undertake studies to confirm their local epidemiology, develop surveillance methodologies using verifiable data sources, and commit resources to sepsis according to their public health priorities. 10 With additional work, we can remove uncertainties in national incidence and longitudinal changes and leverage the enormous investment by GBD to facilitate national sepsis surveillance in countries with both high and low incomes, to effectuate international sepsis quality improvement. Although the scientific purist might prefer to wait for medical statistics to be nosologically exact, 11 this new benchmark in global sepsis epidemiology is an enormous step and is the foundation for initiatives that can ultimately eliminate sepsis. Cataract surgery is one of the most commonly performed operations. Lasers are used for many applications in ophthalmology; however, their use in cataract surgery is fairly recent. On introduction to clinical practice, laser cataract surgery platforms were marketed as bringing a stepwise improvement in surgical technique and were used as a differentiating factor between many cataract surgery providers. The surgical steps automated in femtosecond laser-assisted cataract surgery (FLACS) are corneal incisions, opening of the crystalline lens capsule (capsulotomy), and crystalline lens fragmentation, with less phacoemulsification (ultrasound) energy subsequently needed to complete lens removal. Additional corneal incisions for astigmatism correction can also be done by some FLACS platforms. The cost of FLACS remains high, reflecting in part the development costs. For example, Alcon acquired the LenSx laser system for US$744 million in 2010 1 and Abbott Medical Optics purchased the OptiMedica Catalys laser system for up to $400 million in 2013. 2 Although the steps done by laser are precise and reproducible, 3-5 the frequency of complications with the conventional surgical technique (phacoemulsification) is already low. A Cochrane review of FLACS versus conventional phacoemulsification cataract surgery in 2016 concluded that insufficient evidence was available to determine equivalence or superiority and that large adequately powered randomised controlled trials (RCTs) were needed. 6 A number of other meta-analyses have been published, 7-9 one of which found superior refractive outcomes for FLACS, whereas the others found no significant differences in terms of overall complications or visual and refractive outcomes. A 2019 singlecentre RCT 10 in the UK of 400 eyes in 400 patients found no difference in visual or refractive outcomes between the surgical methods. Other RCTs are still pending publication of their outcomes, including the UK multicentre National Institute for Health Research FACT trial (ISRCTN77602616). 11 Cedric Schweitzer and colleagues 12 report in The Lancet the findings of FLACS versus phacoemulsification cataract surgery (FEMCAT), a multi centre, participantmasked RCT funded by the French Ministry of Health. Of the 907 patients randomly assigned, 870 were analysed with 440 (704 eyes) allocated to receive FLACS and 430 (685 eyes) allocated to receive conventional phacoemulsification cataract surgery in the modified intention-to-treat (mITT) population. No difference was found between the allocation groups for the trial primary outcome, a composite score of outcome measures that covered visual, refractive, and safety outcomes at 3 months postoperatively. The study also found that FLACS was not cost-effective for the French health-care system.
FEMCAT was a large, well designed trial involving 21 surgeons of different training grades from five hospitals in France, and included a sham laser procedure for patients allocated to the conventional phacoemulsification arm. Overall the authors believe the trial to be as representative as possible of the current standard of care for cataract surgery in France.
Some details regarding the FLACS procedure in the trial are particularly noteworthy. The conversion frequency from FLACS to conventional phacoemulsification cataract surgery was high, with 63 eyes (9%) in 63 patients (14%) having to convert. 12 These conversions were predominantly due to technical laser failures (35 [56%] eyes) or poor pupil dilation on the day of surgery (five [8%] eyes), or inability of the patient to be satisfactorily docked to the laser (17 [27%] eyes). Despite this, the frequency of intraoperative surgical complications was low in the mITT population, with posterior capsule rupture in ten (1·4%) of 704 eyes in the FLACS group compared with 11 (1·6%) of 685 eyes in the conventional phacoemulsification group. These are comparable to results from national cataract surgery audits such as the UK National Ophthalmology Database audit, which reported a 1·4% (2551/183 812 eyes) overall posterior capsule rupture rate for the period 2016 to 2017. 13 
